Evidence map›Paper›PMID 36003915›Full record

ReviewFrontiers in cardiovascular medicine2022

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review.

Jinchun Wu, Yanmin Liu, Xiaojuan Wei, Xiaofei Zhang, Yi Ye, Wei Li, Xiaoling Su

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jinchun WuDepartment of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
Yanmin LiuDepartment of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
Xiaojuan WeiDepartment of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
Xiaofei ZhangDepartment of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
Yi YeGraduate School of Qinghai University, Qinghai University, Xining, China.
Wei LiDepartment of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
Xiaoling SuDepartment of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
Qinghai Provincial Peoples Hospital · CNQinghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.

Indexed as

arrhythmiaatrial fibrillationCa2+ homeostasisNa+-Ca2+ exchanger (NCX)Na+-H+ exchanger regulatory factor (NHERF)1/2Na+ homeostasissodium-glucose cotransporter 2 inhibitorventricular arrhythmia (VAs)

Identifiers

PMID36003915
PMCPMC9393294
OpenAlexW4290547743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.